MedTrace Logo

Effect of Casodex on Tumour Hypoxia - Prostate Cancer

NCT00188708 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-18

No results posted yet for this study

Summary

Prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment. One previous study has suggested that hormone therapy, such as Casodex, may improve the prostate oxygen level. This study is designed to test that finding.

Conditions

  • Prostatic Neoplasms

Interventions

PROCEDURE

hypoxia measurement

transrectal oxygen measurement

Sponsors & Collaborators

  • Canadian Cancer Trials Group

    collaborator NETWORK

  • Princess Margaret Hospital, Canada

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Michael Milosevic, MD · Princess Margaret Hospital, Canada

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2022-03-10
Completion
2022-03-10

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00188708 on ClinicalTrials.gov